Israel Expected To OK 5-Year Drug Marketing Exclusivity

Law360, New York (April 21, 2004, 12:00 AM EDT) -- Israel’s cabinet, under pressure from U.S. trade officials, is expected to approve recommendations for drug marketing exclusivity on Sunday, according to a local newspaper report.

The cabinet will hasten approval of the recommendations of an interministerial committee for protecting intellectual property rights for pharmaceuticals, Globes, a business daily, reported on Wednesday.

The interministerial committee recommends setting marketing exclusivity in Israel for international pharmaceutical companies for non-patented ethical drugs, and for drugs whose patents have expired, due to prolonged clinical trials. The five-year exclusivity period will apply...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.